Amneal and mAbxience have announced a further collaboration that will see Amneal gain US rights to mAbxience’s denosumab biosimilars. The two denosumab products reference Amgen’s Prolia and Xgeva brands that treat bone metastasis from cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. The partnering companies have previously allied on a bevacizumab biosimilar that Amneal currently markets in the US.
Noting that mAbxience has “over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals,” Amneal said that...
